Arrowhead's ARO-INHBE obesity trial remains active, not recruiting, with 190 enrolled
Update to the Phase 1/2a study of ARO-INHBE in adults with obesity, alone and with tirzepatide, posted October 30, 2026.
Arrowhead Pharmaceuticals updated its registry record for an ongoing obesity trial this week, with no change to overall status.
- ARO-INHBE, tested alone and with tirzepatide in adults with obesity with and without type 2 diabetes, is a Phase 1/2a trial sponsored by Arrowhead Pharmaceuticals. The study's double-blind dose-escalating design evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of ARO-INHBE, including combination dosing with tirzepatide across three study parts.1
- The record lists overall status as active not recruiting, with an actual start date of December 4, 2024.1 Enrollment reached 190 participants (actual).1
- Primary completion is estimated for October 15, 2027, with study completion estimated for February 15, 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.